A股異動 | 華邦健康(002004.SZ)漲6% 擬轉讓穎泰生物12.31%股份
格隆匯9月6日丨華邦健康(002004.SZ)股價繼續走強,現報6.8元創三個月新高,漲幅6.25%,最新總市值134.6億。公司3日公吿稱,擬8億元人民幣轉讓穎泰生物12.31%股份。完成後,司持有穎泰生物的股份比例由現有的66.76%降低為54.44%。公吿指,通過降低穎泰生物的持股比例,引入戰略投資者,有助於穎泰生物與新安股份優勢互補,促進雙方在技術研發、生產基地、市場渠道、產業鏈管理等方面協同,進一步優化產品和產業佈局,提升穎泰生物核心競爭力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.